Research
-

Who Invented Tesamorelin? The TH9507 Origin
Theratechnologies discovered tesamorelin in 1995. Its early code, TH9507, connects the Montreal laboratory work to human studies and Egrifta.
-

Pharmacokinetics vs Pharmacodynamics Explained
Pharmacokinetics tracks what happens to a medicine; pharmacodynamics tracks its effects. Semax and Selank studies show why blood levels and health benefits are different findings.
-

STEP 3 Trial Results: What the 16% Included
Average weight loss was 16.0% with semaglutide versus 5.7% with placebo. Both groups had intensive behavioral support, so the added difference matters.
-

Why Is World Diabetes Day November 14?
November 14 honors Frederick Banting's birthday. The campaign began in 1991; UN recognition followed in 2006, with annual UN observance starting in 2007.
-

DSIP 1987 Sleep Study: Why the Results Were Weak
A six-person crossover study found little practical sleep benefit. Its stage 2 findings came with a crucial problem: the differences existed before treatment.
-

What Is a Clinical Hold? FDA Pauses Explained
A clinical hold is an FDA order that delays or stops specified research in people. Lifting it lets that research proceed; it doesn't grant permission to market the drug.
-

CAMEO-SEMA Trial: Lower Heart-Filling Pressure
A small semaglutide trial found lower heart-filling pressure during exercise. Its remission result describes pressure tests, not freedom from heart failure.
-

FDA GLP-1 Vision Warning: Label Changes Required
FDA now requires a warning about rare optic-nerve injury across GLP-1 medicines. Here are the reported rates, urgent symptoms and treatment questions.
-

Foundayo Sleep Apnea: Fewer Breathing Pauses
Foundayo reduced breathing interruptions in two year-long trials. The pill is not authorized to treat sleep apnea, and airway treatment still needs reassessment.
-

Health Canada Peptide Warning: Bacteria Found
Bacteria were found in seized injectable products. The Canadian advisories explain a contamination risk, not a confirmed count of patient infections.
-

Hims FTC Lawsuit: Five States Join a Pending Case
Five more states joined the case over alleged health-data sharing and subscription practices. Hims says it will defend the claims; the case remains pending.
-

Hims Zepbound Deal Adds a Route to Lilly’s Brands
The November 6 agreement concerns branded Zepbound and Foundayo. It changes the access route while leaving the prescription decision with the clinician and patient.
-

Semaglutide Gene Study: A Clue to Slow Weight Loss
A new study linked rare gene changes to less weight loss on semaglutide. The finding concerns a tiny group and doesn't make genetic testing routine.
-

Stopping GLP-1 Heart Risk: What Higher Rates Mean
A new study links stopping GLP-1 treatment with more heart attacks, strokes or deaths in people with type 2 diabetes. The reasons people stopped may explain part of the difference.
-

Tirzepatide Resistance Training: Strength Rose
A new 120-person trial found better strength and less loss of tissue that includes muscle, organs and water. Training did not prevent all loss.
-

Tirzepatide vs Semaglutide Muscle Loss: No Winner
A new health-record study links greater lean-mass loss on tirzepatide to greater weight loss. It does not establish which medicine better protects muscle.
-

Contraindication vs Warning: What the Label Means
A contraindication identifies a situation where a medicine should not be used. Warnings and precautions explain risks and what a provider needs to consider.
-

Nicotinamide Riboside Heart Failure Trial: Results
A 30-person study found that swallowed NR raised blood NAD and was generally tolerated. It did not establish better heart function or fewer hospital stays.
-

SUSTAIN 7 Trial Results: Blood Sugar and Weight
Semaglutide had larger blood-sugar and weight changes in this 40-week diabetes trial. The four study doses and who took part set the limits of that finding.
-

Thymosin Alpha 1 Melanoma Trial: What It Found
Two groups reached the target for tumor shrinkage in this 488-person study. A survival benefit was not established, and cancer care has changed since then.
Page 2 of 10 · 199 articles